NurExone Biologic Inc.
NRXBF
$0.50
-$0.0122-2.38%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.37% | 24.47% | 35.84% | -3.18% | -48.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.90% | 12.08% | 14.19% | -4.27% | -33.96% |
| Operating Income | -36.90% | -12.08% | -14.19% | 4.27% | 33.96% |
| Income Before Tax | -38.54% | -8.09% | -9.00% | 41.20% | 55.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.54% | -8.09% | -9.00% | 41.20% | 55.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.54% | -8.09% | -9.00% | 41.20% | 55.44% |
| EBIT | -36.90% | -12.08% | -14.19% | 4.27% | 33.96% |
| EBITDA | -36.54% | -11.70% | -13.30% | 5.06% | -9.60% |
| EPS Basic | 4.23% | 20.18% | 14.67% | 55.31% | 66.72% |
| Normalized Basic EPS | 3.88% | 20.18% | 13.84% | 32.24% | 55.48% |
| EPS Diluted | 4.23% | 20.18% | 14.67% | 55.31% | 66.72% |
| Normalized Diluted EPS | 3.88% | 20.18% | 13.84% | 32.24% | 55.48% |
| Average Basic Shares Outstanding | 42.30% | 33.69% | 27.58% | 23.76% | 26.40% |
| Average Diluted Shares Outstanding | 42.30% | 33.69% | 27.58% | 23.76% | 26.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |